Bloomberg Intelligence Gold Reasserts Lead Over Bitcoin as Top Hedge
Nov 24, 2025
Mike McGlone, Senior Commodity Strategist at Bloomberg Intelligence, explains why gold has reemerged as a superior hedge compared to Bitcoin, especially amid recent market turbulence. Sam Fazeli, Senior Pharmaceuticals Analyst, shares insights on the failed clinical trials of a pill version of Ozempic for Alzheimer's, highlighting the complexities of developing effective treatments. Media analyst Matthew Shettenhelm discusses the implications of easing broadcasting regulations, driven by President Trump's unpredictable tweets, and its impact on industry consolidation.
AI Snips
Chapters
Transcript
Episode notes
Bitcoin Lacks Commodity Fundamentals
- Mike McGlone argues Bitcoin behaves more like a speculative digital asset than a commodity with underlying fundamentals.
- He expects a purge of many altcoins and views $50,000 as a likely near-term Bitcoin support level.
ETFs Fueled A Retail-Driven Peak
- ETFs shifted Bitcoin ownership from insiders to broad retail, creating a plateau after the initial rally.
- McGlone calls the ETF-driven surge classic peak-bubble behavior prone to reversal.
Test Higher Doses Before Abandoning Alzheimer Uses
- Sam Fazeli says more trials are needed before dismissing GLP-1 drugs for Alzheimer's and suggests testing higher-exposure injectables.
- He urges larger firms with deep pockets to consider funding further research despite recent failures.